Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lessened its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 9.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,861,666 shares of the company's stock after selling 301,765 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 4.88% of Twist Bioscience worth $129,290,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. American International Group Inc. boosted its holdings in Twist Bioscience by 0.8% in the 1st quarter. American International Group Inc. now owns 28,506 shares of the company's stock valued at $978,000 after purchasing an additional 213 shares during the period. Caprock Group LLC grew its position in Twist Bioscience by 2.9% in the second quarter. Caprock Group LLC now owns 7,851 shares of the company's stock worth $387,000 after acquiring an additional 220 shares in the last quarter. Signaturefd LLC boosted its holdings in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares in the last quarter. Arizona State Retirement System raised its holdings in shares of Twist Bioscience by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 16,187 shares of the company's stock valued at $798,000 after buying an additional 308 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Twist Bioscience by 3.5% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company's stock worth $457,000 after acquiring an additional 312 shares during the last quarter.

Twist Bioscience Price Performance

Twist Bioscience stock traded down $2.48 during mid-day trading on Thursday, reaching $40.01. 489,905 shares of the company traded hands, compared to its average volume of 939,006. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of -11.12 and a beta of 1.78. The firm's fifty day moving average is $43.92 and its two-hundred day moving average is $45.93. Twist Bioscience Co. has a fifty-two week low of $18.80 and a fifty-two week high of $60.90.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Barclays cut their price target on shares of Twist Bioscience from $60.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, August 5th. Robert W. Baird lifted their price objective on Twist Bioscience from $40.00 to $46.00 and gave the stock an "outperform" rating in a report on Monday, August 5th. JPMorgan Chase & Co. raised their price target on Twist Bioscience from $28.00 to $35.00 and gave the stock an "underweight" rating in a research note on Monday, August 5th. Leerink Partners increased their target price on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. Finally, Evercore ISI raised their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $51.22.

Insider Activity at Twist Bioscience

In other news, insider Dennis Cho sold 1,507 shares of the business's stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the transaction, the insider now owns 91,163 shares of the company's stock, valued at $4,375,824. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, COO Patrick John Finn sold 10,340 shares of Twist Bioscience stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $48.00, for a total transaction of $496,320.00. Following the transaction, the chief operating officer now owns 221,061 shares in the company, valued at approximately $10,610,928. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Dennis Cho sold 1,507 shares of Twist Bioscience stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $72,336.00. Following the transaction, the insider now owns 91,163 shares in the company, valued at approximately $4,375,824. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock worth $4,391,151 over the last three months. Company insiders own 3.92% of the company's stock.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.